{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:58:54Z","timestamp":1793321934275,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common primary liver cancers. Little is known about the combined hepatocellular-cholangiocarcinoma (cHCC-ICC) variant and the proper therapeutic strategies. Out of over 1200 available studies about cHCC-ICC, we selected the most representative ones that reflected updated information with application to individualized therapy. Based on literature data and own experience, we hypothesize that two molecular groups of cHCC-ICC can be identified. The proposed division might have a significant therapeutic role. Most cases develop, like HCC, on a background of cirrhosis and hepatitis and share characteristics with HCC; thus, they are named HCC-type cHCC-ICC and therapeutic strategies might be like those for HCC. This review also highlights a new carcinogenic perspective and identifies, based on literature data and the own experience, a second variant of cHCC-ICC called ICC-type cHCC-ICC. Contrary to HCC, these cases show a tendency for lymph node metastases and ICC components in the metastatic tissues. No guidelines have been established yet for such cases. Individualized therapy should be, however, oriented toward the immunoprofile of the primary tumor and metastatic cells, and different therapeutic strategies should be used in patients with HCC- versus ICC-type cHCC-ICC.<\/jats:p>","DOI":"10.1007\/s00432-024-05781-8","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:01:55Z","timestamp":1716436915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies"],"prefix":"10.1007","volume":"150","author":[{"given":"Simona","family":"Gurzu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Szodorai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Banias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"3","key":"5781_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.21873\/cgp.20445","volume":"21","author":"J Akiba","year":"2024","unstructured":"Akiba J, Ogasawara S, Yano H (2024) Genetic analyses of primary liver cancer cell lines: correspondence with morphological features of original tumors. Cancer Genomics Proteomics 21(3):260\u2013271. https:\/\/doi.org\/10.21873\/cgp.20445","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"5781_CR2","first-page":"647","volume":"25","author":"RA Allen","year":"1949","unstructured":"Allen RA, Lisa JR (1949) Combined liver cell and bile duct carcinoma. Am J Pathol 25(4):647\u2013655","journal-title":"Am J Pathol"},{"key":"5781_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.570958","volume":"10","author":"AA Azizi","year":"2020","unstructured":"Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B (2020) Update on the genetics of and systemic therapy options for combined hepatocellular cholangiocarcinoma. Front Oncol 10:570958. https:\/\/doi.org\/10.3389\/fonc.2020.570958","journal-title":"Front Oncol"},{"issue":"3","key":"5781_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2217\/hep.15.8","volume":"2","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Paradis V, Sempoux C, Theise ND (2015) Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. Hepat Oncol 2(3):255\u2013273. https:\/\/doi.org\/10.2217\/hep.15.8","journal-title":"Hepat Oncol"},{"issue":"1","key":"5781_CR5","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1038\/s41467-023-43749-3","volume":"14","author":"J Calderaro","year":"2023","unstructured":"Calderaro J, Ghaffari Laleh N, Zeng Q, Maille P, Favre L, Pujals A et al (2023) Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nat Commun 14(1):8290. https:\/\/doi.org\/10.1038\/s41467-023-43749-3","journal-title":"Nat Commun"},{"issue":"6","key":"5781_CR6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/jgh.12143","volume":"28","author":"J Cao","year":"2013","unstructured":"Cao J, Huang L, Liu C, Li J, Zhang X, Shen J, Li J, Lu L, Xu F, Yan J, Wu M, Lau WY, Yan Y (2013) Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: a clinicopathologic study of 35 resected cases. J Gastroenterol Hepatol 28(6):1025\u20131031. https:\/\/doi.org\/10.1111\/jgh.12143","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"5781_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121319","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Lang H, Zhang S, Luo Y, Zhang J (2015) S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through \u03b2-catenin in pancreatic cancer cell line. PLoS ONE 10(3):e0121319. https:\/\/doi.org\/10.1371\/journal.pone.0121319","journal-title":"PLoS ONE"},{"key":"5781_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110413","volume":"129","author":"Y Chen","year":"2020","unstructured":"Chen Y, Fan Y, Guo DY, Xu B, Shi XY, Li JT, Duan LF (2020) Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells. Biomed Pharmacother 129:110413. https:\/\/doi.org\/10.1016\/j.biopha.2020.110413","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"5781_CR9","doi-asserted-by":"publisher","first-page":"e1774","DOI":"10.1002\/onco.13893","volume":"26","author":"PD Chen","year":"2021","unstructured":"Chen PD, Chen LJ, Chang YJ, Chang YJ (2021) Long-term survival of combined hepatocellular-cholangiocarcinoma: a nationwide study. Oncologist 26(10):e1774\u2013e1785. https:\/\/doi.org\/10.1002\/onco.13893","journal-title":"Oncologist"},{"key":"5781_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.977111","volume":"12","author":"G Deng","year":"2023","unstructured":"Deng G, Ren JK, Wang HT, Deng L, Chen ZB, Fan YW, Tang YJ, Zhang T, Tang D (2023) Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy. Front Oncol 12:977111. https:\/\/doi.org\/10.3389\/fonc.2022.977111","journal-title":"Front Oncol"},{"issue":"3","key":"5781_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4254\/wjh.v11.i3.0000","volume":"11","author":"D Fodor","year":"2019","unstructured":"Fodor D, Jung I, Turdean S, Satala C, Gurzu S (2019) Angiogenesis of hepatocellular carcinoma: an immunohistochemistry study. World J Hepatol 11(3):294\u2013304. https:\/\/doi.org\/10.4254\/wjh.v11.i3.0000","journal-title":"World J Hepatol"},{"issue":"8","key":"5781_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/lt.23897","volume":"20","author":"M Garancini","year":"2014","unstructured":"Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, Giardini V (2014) Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 20(8):952\u2013959. https:\/\/doi.org\/10.1002\/lt.23897","journal-title":"Liver Transpl"},{"key":"5781_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12503","author":"E Gigante","year":"2023","unstructured":"Gigante E, Bouattour M, Bedoya JU, Regnault H, Ziol M, Assenat E, Paradis V, Calderaro J, Ganne-Carri\u00e9 N, Bouhier-Leporrier K, Amaddeo G, Nault JC (2023) Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study. United Eur Gastroenterol J. https:\/\/doi.org\/10.1002\/ueg2.12503","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"5781_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/1097-0142(19850101)55:1<124::AID-CNCR2820550120>3.0.CO;2-Z","volume":"55","author":"ZD Goodman","year":"1985","unstructured":"Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55(1):124\u2013135","journal-title":"Cancer"},{"issue":"5","key":"5781_CR15","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1007\/s00261-016-1038-7","volume":"42","author":"KW Gu","year":"2017","unstructured":"Gu KW, Kim YK, Min JH, Ha SY, Jeong WK (2017) Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Abdom Radiol 42(5):1424\u20131433. https:\/\/doi.org\/10.1007\/s00261-016-1038-7","journal-title":"Abdom Radiol"},{"issue":"8","key":"5781_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071530","volume":"8","author":"S Gurzu","year":"2013","unstructured":"Gurzu S, Ciortea D, Munteanu T, Kezdi-Zaharia I, Jung I (2013) Mesenchymal-to-endothelial transition in Kaposi sarcoma: a histogenetic hypothesis based on a case series and literature review. PLoS ONE 8(8):e71530. https:\/\/doi.org\/10.1371\/journal.pone.0071530","journal-title":"PLoS ONE"},{"issue":"29","key":"5781_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001189","volume":"94","author":"S Gurzu","year":"2015","unstructured":"Gurzu S, Jung I, Contac AO, Turcu M, Tudor A (2015) Atypical hepatocellular neoplasm with peliosis in cirrhotic liver versus hepatocellular carcinoma: a diagnostic trap. Medicine (baltimore) 94(29):e1189. https:\/\/doi.org\/10.1097\/MD.0000000000001189","journal-title":"Medicine (baltimore)"},{"key":"5781_CR18","doi-asserted-by":"publisher","first-page":"2962580","DOI":"10.1155\/2019\/2962580","volume":"2019","author":"S Gurzu","year":"2019","unstructured":"Gurzu S, Kobori L, Fodor D, Jung I (2019) Epithelial mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: a review. BioMed Res Int 2019:2962580. https:\/\/doi.org\/10.1155\/2019\/2962580","journal-title":"BioMed Res Int"},{"issue":"4","key":"5781_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00418-021-02006-8","volume":"156","author":"S Gurzu","year":"2021","unstructured":"Gurzu S, Sugimura H, Szederjesi J, Szodorai R, Braicu C, Kobori L, Fodor D, Jung I (2021) Interaction between cadherins, vimentin and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma. Histochem Cell Biol 156(4):377\u2013390. https:\/\/doi.org\/10.1007\/s00418-021-02006-8","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"5781_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021","volume":"4","author":"A Holczbauer","year":"2021","unstructured":"Holczbauer A, Wangensteen KJ, Shin S (2021) Cellular origins of regenerating liver and hepatocellular carcinoma. JHEP Rep 4(4):100416. https:\/\/doi.org\/10.1016\/j.jhepr.2021","journal-title":"JHEP Rep"},{"issue":"1","key":"5781_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00261-017-1261-x","volume":"43","author":"N Horvat","year":"2018","unstructured":"Horvat N, Nikolovski I, Long N, Gerst S, Zheng J, Pak LM, Simpson A, Zheng J, Capanu M, Jarnagin WR, Mannelli L, Do RKG (2018) Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014. Abdom Radiol (NY) 43(1):169\u2013178. https:\/\/doi.org\/10.1007\/s00261-017-1261-x","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"5781_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3892\/ijo.2013.2038","volume":"43","author":"Y Ishii","year":"2013","unstructured":"Ishii Y, Sasaki T, Serikawa M, Minami T, Okazaki A, Yukutake M, Ishigaki T, Kosaka K, Mouri T, Yoshimi S, Shimizu A, Tsuboi T, Chayama K (2013) Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: \u03b9mplications for cholangiocarcinogenesis. Int J Oncol 43(4):1073\u20131079. https:\/\/doi.org\/10.3892\/ijo.2013.2038","journal-title":"Int J Oncol"},{"issue":"7","key":"5781_CR23","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1002\/cncr.10392","volume":"94","author":"WR Jarnagin","year":"2002","unstructured":"Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94(7):2040\u20132046. https:\/\/doi.org\/10.1002\/cncr.10392","journal-title":"Cancer"},{"issue":"3","key":"5781_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00268-016-3787","volume":"41","author":"DH Jung","year":"2017","unstructured":"Jung DH, Hwang S, Kim KH, Hong SM, Lee YJ, Ahn CS, Moon DB, Ha TY, Song GW, Park GC, Yu ES, Lee SG (2017) Clinicopathological features and post-resection prognosis of double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Surg 41(3):825\u2013834. https:\/\/doi.org\/10.1007\/s00268-016-3787","journal-title":"World J Surg"},{"issue":"10","key":"5781_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00595-006-3276-8","volume":"36","author":"WS Lee","year":"2006","unstructured":"Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36(10):892\u2013897. https:\/\/doi.org\/10.1007\/s00595-006-3276-8","journal-title":"Surg Today"},{"issue":"1","key":"5781_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MCG.0b013e3181ce5dfa","volume":"45","author":"JH Lee","year":"2011","unstructured":"Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, Yoon JH, Lee HS, Yi NJ, Suh KS, Lee KU, Jang JJ, Kim YJ (2011) Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45(1):69\u201375. https:\/\/doi.org\/10.1097\/MCG.0b013e3181ce5dfa","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"5781_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1440-1746.2012.07289.x","volume":"28","author":"CH Lee","year":"2013","unstructured":"Lee CH, Hsieh SY, Chang CJ, Lin YJ (2013) Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 28(1):122\u2013127. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07289.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"5781_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00109-013-1104-3","volume":"92","author":"Z Li","year":"2014","unstructured":"Li Z, Tang M, Liu S, Zheng Y, Nie C, Yuan Z, Zhou L, Guo G, Wei Y (2014) Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma. J Mol Med 92(3):291\u2013303. https:\/\/doi.org\/10.1007\/s00109-013-1104-3","journal-title":"J Mol Med"},{"key":"5781_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12885-016-2156-x","volume":"16","author":"R Li","year":"2016","unstructured":"Li R, Yang D, Tang CL, Cai P, Ma KS, Ding SY, Zhang XH, Guo DY, Yan XC (2016) Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer 16:158. https:\/\/doi.org\/10.1186\/s12885-016-2156-x","journal-title":"BMC Cancer"},{"issue":"10 HCC","key":"5781_CR30","doi-asserted-by":"publisher","first-page":"e7240","DOI":"10.5812\/hepatmon.7240","volume":"12","author":"C Maletzki","year":"2012","unstructured":"Maletzki C, Bodammer P, Breitr\u00fcck A, Kerkhoff C (2012) S100 Proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon 12(10 HCC):e7240. https:\/\/doi.org\/10.5812\/hepatmon.7240","journal-title":"Hepat Mon"},{"key":"5781_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejro.2014.07.001","volume":"1","author":"S Maximin","year":"2014","unstructured":"Maximin S, Ganeshan DM, Shanbhogue AK, Dighe MK, Yeh MM, Kolokythas O, Bhargava P, Lalwani N (2014) Current update on combined hepatocellular-cholangiocarcinoma. Eur J Radiol Open 1:40\u201348. https:\/\/doi.org\/10.1016\/j.ejro.2014.07.001","journal-title":"Eur J Radiol Open"},{"issue":"11","key":"5781_CR32","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4161\/15384047.2014.956642","volume":"15","author":"G Miolo","year":"2014","unstructured":"Miolo G, Ash A, Buonadonna A, Lo Re G, Torrisi E, Cervo S, Santeufemia DA, Tuzi A, Canzonieri V (2014) Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. Cancer Biol Ther 15(11):1439\u20131443. https:\/\/doi.org\/10.4161\/15384047.2014.956642","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"5781_CR33","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1158\/1078-0432.CCR-21-1219","volume":"28","author":"CT Nguyen","year":"2022","unstructured":"Nguyen CT, Caruso S, Maille P, Beaufrere A, Augustin J, Favre L et al (2022) Immune profiling of combined hepatocellular- cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. Clin Cancer Res 28(3):540\u2013551. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1219","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5781_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 7(6):522\u2013532. https:\/\/doi.org\/10.1016\/S2468-1253(22)00043-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"5781_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/hep.28485","volume":"64","author":"T Oikawa","year":"2016","unstructured":"Oikawa T (2016) Cancer Stem cells and their cellular origins in primary liver and biliary tract cancers. Hepatology 64(2):645\u2013651. https:\/\/doi.org\/10.1002\/hep.28485","journal-title":"Hepatology"},{"issue":"1","key":"5781_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/PAS.0000000000001751","volume":"46","author":"DJ Papke Jr","year":"2022","unstructured":"Papke DJ Jr, Dickson BC, Sholl L, Fletcher CDM (2022) Pseudoendocrine sarcoma: clinicopathologic analysis of 23 cases of a distinctive soft tissue neoplasm with metastatic potential, recurrent CTNNB1 mutations, and a predilection for truncal locations. Am J Surg Pathol 46(1):33\u201343. https:\/\/doi.org\/10.1097\/PAS.0000000000001751","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"5781_CR37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","volume":"8","author":"M Pinter","year":"2023","unstructured":"Pinter M, Scheiner B, Pinato DJ (2023) Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol 8(8):760\u2013770. https:\/\/doi.org\/10.1016\/S2468-1253(23)00147-4","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"5781_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000507320","volume":"13","author":"M Rizell","year":"2020","unstructured":"Rizell M, Aberg F, Perman M, Ny L, Sten L, Hashimi F, Svanvik J, Lindn\u00e9r P (2020) Checkpoint inhibition causing complete remission of metastatic combined hepatocellular-cholangiocarcinoma after hepatic resection. Case Rep Oncol 13(1):478\u2013484. https:\/\/doi.org\/10.1159\/000507320","journal-title":"Case Rep Oncol"},{"issue":"2","key":"5781_CR39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cancers15020494","volume":"15","author":"F Ro\u00dfner","year":"2023","unstructured":"Ro\u00dfner F, Sinn BV, Horst D (2023) Pathology of combined hepatocellular carcinoma-cholangiocarcinoma: an update. Cancers (basel) 15(2):494. https:\/\/doi.org\/10.3390\/cancers15020494","journal-title":"Cancers (basel)"},{"issue":"7","key":"5781_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6129","volume":"10","author":"N Saito","year":"2022","unstructured":"Saito N, Hatanaka T, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Yoshinaga T, Kashiwabara K, Kubo N, Hosouchi Y, Tojima H, Kakizaki S, Uraoka T (2022) A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab. Clin Case Rep 10(7):e6129. https:\/\/doi.org\/10.1002\/ccr3.6129","journal-title":"Clin Case Rep"},{"issue":"3","key":"5781_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bjc.2017.413","volume":"118","author":"M Salimon","year":"2018","unstructured":"Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y (2018) Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer 118(3):325\u2013330. https:\/\/doi.org\/10.1038\/bjc.2017.413","journal-title":"Br J Cancer"},{"issue":"1","key":"5781_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","volume":"267","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, Endo I, Pawlik TM (2018) The tumor burden score: a new \u201cMetro-ticket\u201d prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267(1):132\u2013141. https:\/\/doi.org\/10.1097\/SLA.0000000000002064","journal-title":"Ann Surg"},{"key":"5781_CR43","doi-asserted-by":"publisher","first-page":"1234113","DOI":"10.3389\/fonc.2023.1234113","volume":"13","author":"T Satake","year":"2023","unstructured":"Satake T, Shibuki T, Watanabe K, Sasaki M, Imaoka H, Mitsunaga S, Kojima M, Ikeda M (2023) Case report: atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma. Front Oncol 13:1234113. https:\/\/doi.org\/10.3389\/fonc.2023.1234113","journal-title":"Front Oncol"},{"issue":"1","key":"5781_CR44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12029-020-00394-z","volume":"52","author":"CB Satala","year":"2021","unstructured":"Satala CB, Jung I, Kobori L, Kovacs Z, Fodor D, Szodorai R, Gurzu S (2021) Benefits of the 8th American joint committee on cancer system for hepatocellular carcinoma staging. J Gastrointest Cancer 52(1):243\u2013248. https:\/\/doi.org\/10.1007\/s12029-020-00394-z","journal-title":"J Gastrointest Cancer"},{"key":"5781_CR45","first-page":"260","volume-title":"WHO classification of tumors of the digestive system","author":"C Sempoux","year":"2019","unstructured":"Sempoux C, Kakar S, Kondo F, Schirmacher P (2019) Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: Loukuhetty D, White VA, Watanabe R, Cree IA (eds) WHO classification of tumors of the digestive system, 5th edn. International Agency for Research on Cancer, Lyon, France, pp 260\u2013262","edition":"5"},{"key":"5781_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-023-01682-x","author":"R Sheng","year":"2023","unstructured":"Sheng R, Yang C, Zhang Y, Wang H, Zheng B, Han J, Sun W, Zeng M (2023) The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value. Radiol Med. https:\/\/doi.org\/10.1007\/s11547-023-01682-x","journal-title":"Radiol Med"},{"key":"5781_CR47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/1097-0142(195907\/08)12:4<753::AID-CNCR2820120420>3.0.CO;2-L","volume":"12","author":"PE Steiner","year":"1959","unstructured":"Steiner PE, Higgison J (1959) Cholangiolocellular carcinoma of the liver. Cancer 12:753\u2013759","journal-title":"Cancer"},{"issue":"42","key":"5781_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001848","volume":"94","author":"BA Suciu","year":"2015","unstructured":"Suciu BA, Gurzu S, Marginean L, Milutin D, Halmaciu I, Jung I, Branzaniuc K, Molnar C (2015) Significant shrinkage of multifocal liver metastases and long-term survival in a patient with rectal cancer, after trans-arterial chemoembolization (TACE): a case report. Medicine (baltimore) 94(42):e1848. https:\/\/doi.org\/10.1097\/MD.0000000000001848","journal-title":"Medicine (baltimore)"},{"key":"5781_CR49","doi-asserted-by":"publisher","first-page":"vii15","DOI":"10.1093\/annonc\/mdz413.054","volume":"30","author":"E Tahover","year":"2019","unstructured":"Tahover E (2019) An exceptional response to immunotherapy doublet in combined hepatocellular carcinoma-cholangiocarcinoma. Ann Oncol 30:vii15. https:\/\/doi.org\/10.1093\/annonc\/mdz413.054","journal-title":"Ann Oncol"},{"issue":"7","key":"5781_CR50","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.gassur.2006.01.018","volume":"10","author":"D Tang","year":"2006","unstructured":"Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M (2006) Clinical and pathological features of Allen\u2019s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 10(7):987\u2013998. https:\/\/doi.org\/10.1016\/j.gassur.2006.01.018","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"5781_CR51","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.6004\/jnccn.2018.7053","volume":"16","author":"NA Trikalinos","year":"2018","unstructured":"Trikalinos NA, Zhou A, Doyle MBM, Fowler KJ, Morton A, Vachharajani N, Amin M, Keller JW, Chapman WC, Brunt EM, Tan BR (2018) Systemic therapy for combined hepatocellular-cholangiocarcinoma: a single-institution experience. J Natl Compr Cancer Netw 16(10):1193\u20131199. https:\/\/doi.org\/10.6004\/jnccn.2018.7053","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3 Suppl.","key":"5781_CR52","first-page":"719","volume":"53","author":"S Turdean","year":"2012","unstructured":"Turdean S, Gurzu S, Turcu M, Voidazan S, Sin A (2012) Current data in clinicopathological characteristics of primary hepatic tumors. Rom J Morphol Embryol 53(3 Suppl.):719\u2013724","journal-title":"Rom J Morphol Embryol"},{"key":"5781_CR53","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3071-23","author":"S Unome","year":"2024","unstructured":"Unome S, Imai K, Miwa T, Hanai T, Suetsugu A, Takai K, Suzui N, Miyazaki T, Shimizu M (2024) A Case of unresectable combined hepatocellular-cholangiocarcinoma treated with combination therapy consisting of durvalumab plus tremelimumab. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.3071-23","journal-title":"Intern Med"},{"issue":"14","key":"5781_CR54","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/hmg\/ddad077","volume":"32","author":"J Vinay","year":"2023","unstructured":"Vinay J, Palo A, Besra K, Dixit M (2023) Gallbladder cancer-associated genetic variants rs1003349 and rs1004030 regulate MMP14 expression by altering SOX10- and MYB-binding sites. Hum Mol Genet 32(14):2357\u20132372. https:\/\/doi.org\/10.1093\/hmg\/ddad077","journal-title":"Hum Mol Genet"},{"key":"5781_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4137\/cpath.s500","volume":"1","author":"MS Wachtel","year":"2008","unstructured":"Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE (2008) Combined hepatocellular cholangiocarcinomas: analysis of a large database. Clin Med Pathol 1:43\u201347. https:\/\/doi.org\/10.4137\/cpath.s500","journal-title":"Clin Med Pathol"},{"issue":"24","key":"5781_CR56","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41388-018-0188-1","volume":"37","author":"J Wang","year":"2018","unstructured":"Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X (2018) Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene 37(24):3229\u20133242. https:\/\/doi.org\/10.1038\/s41388-018-0188-1","journal-title":"Oncogene"},{"key":"5781_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00000441-190309000-00004","volume":"126","author":"HG Wells","year":"1903","unstructured":"Wells HG (1903) Primary carcinoma of the liver. Am J Med Sci 126:403\u2013417","journal-title":"Am J Med Sci"},{"issue":"4","key":"5781_CR58","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.transproceed.2015.11.029","volume":"48","author":"CH Wu","year":"2016","unstructured":"Wu CH, Yong CC, Liew EH, Tsang LL, Lazo M, Hsu HW, Ou HY, Yu CY, Chen TY, Huang TL, Concejero AM, Chen CL, Cheng YF (2016) Combined hepatocellular carcinoma and cholangiocarcinoma: diagnosis and prognosis after resection or transplantation. Transpl Proc 48(4):1100\u20131104. https:\/\/doi.org\/10.1016\/j.transproceed.2015.11.029","journal-title":"Transpl Proc"},{"issue":"23","key":"5781_CR59","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.3748\/wjg.v21.i23.7335","volume":"219","author":"S Xiang","year":"2015","unstructured":"Xiang S, Chen YF, Guan Y, Chen XP (2015) Primary combined hepatocellular-cholangiocellular sarcoma: an unusual case. World J Gastroenterol 219(23):7335\u20137342. https:\/\/doi.org\/10.3748\/wjg.v21.i23.7335","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5781_CR60","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.asjsur.2022.10.007","volume":"46","author":"Z Xu","year":"2023","unstructured":"Xu Z, Ma J, Chen T, Yang Y (2023) Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: report of two cases. Asian J Surg 46(4):1741\u20131742. https:\/\/doi.org\/10.1016\/j.asjsur.2022.10.007","journal-title":"Asian J Surg"},{"issue":"6","key":"5781_CR61","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ccell.2019.04.007","volume":"35","author":"R Xue","year":"2019","unstructured":"Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, Li Y, Wang J, Guo H, Huang QT, Zhong Q, Tan J, Qi L, Gong W, Hong Z, Li M, Zhao J, Peng T, Lu Y, Lim KHT, Boot A, Ono A, Chayama K, Zhang Z, Rozen SG, Teh BT, Wang XW, Nakagawa H, Zeng MS, Bai F, Zhang N (2019) Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35(6):932-947.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.04.007","journal-title":"Cancer Cell"},{"issue":"4","key":"5781_CR62","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","volume":"9","author":"T Yau","year":"2024","unstructured":"Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L (2024) Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol 9(4):310\u2013322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00454-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"5781_CR63","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1245\/s10434-012-2328-0","volume":"19","author":"X Yin","year":"2012","unstructured":"Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19(9):2869\u20132876. https:\/\/doi.org\/10.1245\/s10434-012-2328-0","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"5781_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100042","volume":"36","author":"N Yoshuantari","year":"2023","unstructured":"Yoshuantari N, Jeng YM, Liau JY, Lee CH, Tsai JH (2023) Hepatic sarcomatoid carcinoma is an aggressive hepatic neoplasm sharing common molecular features with its conventional carcinomatous counterparts. Mod Pathol 36(1):100042. https:\/\/doi.org\/10.1016\/j.modpat.2022.100042","journal-title":"Mod Pathol"},{"issue":"4","key":"5781_CR65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00534-011-0417-2","volume":"19","author":"Q Zhan","year":"2012","unstructured":"Zhan Q, Shen BY, Deng XX, Zhu ZC, Chen H, Peng CH, Li HW (2012) Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center. J Hepatobiliary Pancreat Sci 19(4):361\u2013369. https:\/\/doi.org\/10.1007\/s00534-011-0417-2","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"5781_CR66","doi-asserted-by":"publisher","first-page":"goae031","DOI":"10.1093\/gastro\/goae031","volume":"12","author":"YZ Zhang","year":"2024","unstructured":"Zhang YZ, Liu YC, Su T, Shi JN, Huang Y, Liang B (2024) Current advances and future directions in combined hepatocellular and cholangiocarcinoma. Gastroenterol Rep (oxf) 12:goae031. https:\/\/doi.org\/10.1093\/gastro\/goae031","journal-title":"Gastroenterol Rep (oxf)"},{"issue":"1","key":"5781_CR67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40880-016-0146-7","volume":"35","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Yu WL, Lu XY, Dong H, Gu YJ, Sheng X, Cong WM, Wu MC (2016) Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chin J Cancer 35(1):82. https:\/\/doi.org\/10.1186\/s40880-016-0146-7","journal-title":"Chin J Cancer"},{"issue":"1","key":"5781_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ctm2.11","volume":"10","author":"BH Zheng","year":"2020","unstructured":"Zheng BH, Ma JQ, Tian LY, Dong LQ, Song GH, Pan JM, Liu YM, Yang SX, Wang XY, Zhang XM, Zhou J, Fan J, Shi JY, Gao Q (2020) The distribution of immune cells within combined hepatocellular carcinoma and cholangiocarcinoma predicts clinical outcome. Clin Transl Med 10(1):45\u201356. https:\/\/doi.org\/10.1002\/ctm2.11","journal-title":"Clin Transl Med"},{"issue":"14","key":"5781_CR69","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.3748\/wjg.14.2251","volume":"14","author":"YM Zhou","year":"2008","unstructured":"Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B, Liu P, Li ZM (2008) Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein. World J Gastroenterol 14(14):2251\u20132254. https:\/\/doi.org\/10.3748\/wjg.14.2251","journal-title":"World J Gastroenterol"},{"issue":"6","key":"5781_CR70","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ejca.2010.02.005","volume":"46","author":"H Zhou","year":"2010","unstructured":"Zhou H, Wang H, Zhou D, Wang H, Wang Q, Zou S, Tu Q, Wu M, Hu H (2010) Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 46(6):1056\u20131061. https:\/\/doi.org\/10.1016\/j.ejca.2010.02.005","journal-title":"Eur J Cancer"},{"key":"5781_CR71","doi-asserted-by":"publisher","first-page":"1190967","DOI":"10.3389\/fphar.2023.1190967","volume":"14","author":"N Zhou","year":"2023","unstructured":"Zhou N, Lei CF, Tan SR, Huang QY, Zhang SY, Liang ZX, Gou HF (2023) Case report: remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma. Front Pharmacol 14:1190967. https:\/\/doi.org\/10.3389\/fphar.2023.1190967","journal-title":"Front Pharmacol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05781-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05781-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T03:25:28Z","timestamp":1717989928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05781-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5781"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05781-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"270"}}